199 related articles for article (PubMed ID: 24055076)
1. Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opioid receptor selective antagonists.
Zaidi SA; Arnatt CK; He H; Selley DE; Mosier PD; Kellogg GE; Zhang Y
Bioorg Med Chem; 2013 Nov; 21(21):6405-13. PubMed ID: 24055076
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Li G; Aschenbach LC; Chen J; Cassidy MP; Stevens DL; Gabra BH; Selley DE; Dewey WL; Westkaemper RB; Zhang Y
J Med Chem; 2009 Mar; 52(5):1416-27. PubMed ID: 19199782
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.
Yuan Y; Li G; He H; Stevens DL; Kozak P; Scoggins KL; Mitra P; Gerk PM; Selley DE; Dewey WL; Zhang Y
ACS Chem Neurosci; 2011 Jul; 2(7):346-51. PubMed ID: 22816021
[TBL] [Abstract][Full Text] [Related]
5. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models.
Metzger TG; Paterlini MG; Portoghese PS; Ferguson DM
Neurochem Res; 1996 Nov; 21(11):1287-94. PubMed ID: 8947918
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
7. Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators.
Zheng Y; Obeng S; Wang H; Stevens DL; Komla E; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2018 Dec; 9(12):3028-3037. PubMed ID: 30001114
[TBL] [Abstract][Full Text] [Related]
8. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
[TBL] [Abstract][Full Text] [Related]
9. 14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
Li G; Aschenbach LC; He H; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2009 Mar; 19(6):1825-9. PubMed ID: 19217280
[TBL] [Abstract][Full Text] [Related]
10. Exploring the structure of opioid receptors with homology modeling based on single and multiple templates and subsequent docking: a comparative study.
Bera I; Laskar A; Ghoshal N
J Mol Model; 2011 May; 17(5):1207-21. PubMed ID: 20661609
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
Yuan Y; Zaidi SA; Elbegdorj O; Aschenbach LC; Li G; Stevens DL; Scoggins KL; Dewey WL; Selley DE; Zhang Y
J Med Chem; 2013 Nov; 56(22):9156-69. PubMed ID: 24144240
[TBL] [Abstract][Full Text] [Related]
12. 6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.
Williams DA; Zheng Y; David BG; Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Selley DE; Dewey WL; Akbarali HI; Zhang Y
ACS Chem Neurosci; 2016 Aug; 7(8):1120-9. PubMed ID: 27269866
[TBL] [Abstract][Full Text] [Related]
13. Computational insights into the molecular mechanisms of differentiated allosteric modulation at the mu opioid receptor by structurally similar bitopic modulators.
Wang H; Reinecke BA; Zhang Y
J Comput Aided Mol Des; 2020 Aug; 34(8):879-895. PubMed ID: 32193867
[TBL] [Abstract][Full Text] [Related]
14. The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the mu, delta, and kappa opioid receptors.
Xu W; Chen C; Huang P; Li J; de Riel JK; Javitch JA; Liu-Chen LY
Biochemistry; 2000 Nov; 39(45):13904-15. PubMed ID: 11076532
[TBL] [Abstract][Full Text] [Related]
15. Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.
Wang H; Cao D; Gillespie JC; Mendez RE; Selley DE; Liu-Chen LY; Zhang Y
Future Med Chem; 2021 Mar; 13(6):551-573. PubMed ID: 33590767
[TBL] [Abstract][Full Text] [Related]
16. Importance of phenolic address groups in opioid kappa receptor selective antagonists.
Thomas JB; Fix SE; Rothman RB; Mascarella SW; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2004 Feb; 47(4):1070-3. PubMed ID: 14761209
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the amino acid residues in the sixth transmembrane domains accessible in the binding-site crevices of mu, delta, and kappa opioid receptors.
Xu W; Li J; Chen C; Huang P; Weinstein H; Javitch JA; Shi L; de Riel JK; Liu-Chen LY
Biochemistry; 2001 Jul; 40(27):8018-29. PubMed ID: 11434771
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR comparative molecular field analysis on opioid receptor antagonists: pooling data from different studies.
Peng Y; Keenan SM; Zhang Q; Kholodovych V; Welsh WJ
J Med Chem; 2005 Mar; 48(5):1620-9. PubMed ID: 15743203
[TBL] [Abstract][Full Text] [Related]
19. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
[TBL] [Abstract][Full Text] [Related]
20. Structure of the δ-opioid receptor bound to naltrindole.
Granier S; Manglik A; Kruse AC; Kobilka TS; Thian FS; Weis WI; Kobilka BK
Nature; 2012 May; 485(7398):400-4. PubMed ID: 22596164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]